Regeneron Reports Third Quarter 2020 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- Nasdaq futures slide as AI warnings rattle markets; Nvidia, other chip stocks retreat
- Global AI stocks fall as industry chiefs call for slowing development
- Oil prices continue surge, rising 3% amid Saudi pipeline outage after attack
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- Wall Street's new pair trade: Long software, short chips
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Regeneron (REGN) Tops Q3 EPS by $1.23, Revenues Beat
November 5, 2020 6:50 AM ESTRegeneron (NASDAQ: REGN) reported Q3 EPS of $8.36, $1.23 better than the analyst estimate of $7.13. Revenue for the quarter came in at $2.29 billion versus the consensus estimate of $2.09 billion.
Third quarter 2020 revenues increased 32% to $2.29 billion versus third quarter 2019(4)Third quarter 2020 EYLEA® U.S. net sales increased 11% to $1.32 billion versus third quarter 2019Third quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, increased 69% to $1.07 billion versus third quarter 2019Third quarter 2020 GAAP diluted EPS was $7.39... More